Search

Your search keyword '"Joe, W."' showing total 658 results

Search Constraints

Start Over You searched for: Author "Joe, W." Remove constraint Author: "Joe, W." Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
658 results on '"Joe, W."'

Search Results

1. Supplementary Figure 2 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction

2. Data from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction

3. Supplementary Figure 1 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction

4. Supplementary Tables 1-8 from Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction

5. Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction

9. Supplementary Table 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

10. Data from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

11. Data from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

12. Supplementary Table S1 from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer

13. Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers

14. Supplementary Figure 7 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

16. Supplementary Figure 4 from Temporal Dissection of Tumorigenesis in Primary Cancers

17. Supplementary Data from Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer

18. Data from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

19. Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

20. Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers

21. Supplementary Figure 3 from Temporal Dissection of Tumorigenesis in Primary Cancers

25. Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers

26. Supplementary Table 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

27. Data from Temporal Dissection of Tumorigenesis in Primary Cancers

30. Supplementary Table 1 from Temporal Dissection of Tumorigenesis in Primary Cancers

31. Supplementary Table 4 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

32. Supplementary Methods from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

33. Supplementary Table 2 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

34. Supplementary Figure Legends 1-5, Table Legends 1-2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

35. Data from Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer

36. Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

38. Supplementary Data from Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer

39. Supplementary Figure 4 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

40. Supplementary Table 1 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

41. Supplementary Figure 3 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

42. Supplementary Figure 1 from Temporal Dissection of Tumorigenesis in Primary Cancers

43. Supplementary Materials and Methods from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

44. Supplementary Figure 5 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

45. Supplementary Figure 2 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

46. Supplementary Figure 1 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

47. Supplementary Figure 2 from A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

48. Supplementary Figure 4 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

49. Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

50. Supplementary Figure 1 from Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer

Catalog

Books, media, physical & digital resources